Edwards' Resilia tissue, in development for more than two decades, will form the basis of the company's heart valve implants going forward. (Edwards Lifesciences) As it aims to broaden the reach of ...

CAIRO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary RESILIA tissue ...

CHICAGO--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) today announced 10-year results from the COMMENCE aortic trial, reinforcing the long-term durability and sustained performance of its ...

Edwards Lifesciences reported new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary Resilia tissue technology have significantly improved long-term ...

Edwards Lifesciences’ SAPIEN 3 Ultra Resilia transcatheter heart valve combines a low-profile delivery system with treated bovine tissue designed to resist calcification, aiming to extend durability ...

Edwards Lifesciences has earned FDA approval for the first surgical valve replacement designed for patients with tricuspid valve disease, the Triformis Resilia surgical valve replacement. Currently, ...

SINGAPORE, May 4, 2026 /PRNewswire/ -- Edwards Lifesciences, the leading global structural heart innovation company, recently announced 10-year results from the COMMENCE aortic trial, reinforcing the ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...